Evogene Subsidiary Biomica Licenses Cancer Therapeutic BMC128 to Lishan Biotech
EVGN is trading near its 52-week low of $0.93 (11% above the low).
Summary
Evogene's subsidiary, Biomica, entered an exclusive worldwide licensing agreement with Shanghai Lishan Biopharmaceuticals for BMC128, a microbiome-based therapeutic for cancer, which includes milestone payments and royalties.
Key Events · M&A and Partnerships · EVGN
-
Exclusive Global Licensing Agreement
Evogene's subsidiary, Biomica Ltd., granted Shanghai Lishan Biopharmaceuticals Co., Ltd. exclusive worldwide rights to develop, manufacture, and commercialize BMC128.
-
Microbiome-Based Cancer Therapeutic
BMC128 is a first-in-class microbiome-based therapeutic designed to enhance anti-tumor immune activity, currently completing a Phase 1 clinical study with promising early results in renal cell carcinoma and non-small cell lung cancer.
-
Potential Future Revenue Streams
Biomica is eligible to receive development milestone payments, sales milestone payments, and royalties from Lishan Biotech's future sales of BMC128.
-
Advancement to Phase 2 Clinical Study
Lishan Biotech plans to advance BMC128 into a Phase 2 clinical study and pursue regulatory filings in China and the United States.
Analysis · EVGN · Industrial Applications And Services
Evogene's subsidiary, Biomica, has secured a significant global licensing agreement for its microbiome-based therapeutic, BMC128. This partnership with Shanghai Lishan Biopharmaceuticals validates Biomica's research and development capabilities, particularly for a therapeutic that has shown promising early clinical results in Phase 1 studies for renal and lung cancer. For a company of Evogene's size, this agreement represents a crucial non-dilutive funding pathway through potential development milestones and future sales royalties, significantly de-risking the program's advancement and providing a clear path to commercialization without direct financial burden on Biomica. The commitment by Lishan Biotech to advance BMC128 into Phase 2 clinical studies and pursue regulatory filings in major markets like China and the U.S. underscores the potential impact of this therapeutic.
At the time of this filing, EVGN was trading at $1.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.93 to $2.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.